Finally, we suggest that a low ACE/ACE2 ratio and cell sorting according to the cell cycle phase, should be additionally considered among the minimum criteria for establishing stem cell-based products for the treatment of COVID-19. The gene discussed is ACE2; the disease is COVID-19.